FEMY Femasys (FEMY) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001339005
Cluster · 5 insidersActivist 13DC-suite buying · 5
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
What the filings say about FEMY
Insiders, 180 days
+$134.0K net bought
5 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 10.0% of the class
Femasys insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, FEMASYS INC insiders bought a net $134.0K of stock across 5 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 15,625 shares held after it.
- 4 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lee-Sepsick Kathy bought about $50.0K of FEMY on Aug 7, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 15,625 shares held after it.
- 4 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Elefant Dov bought about $50.0K of FEMY on Aug 7, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 4,375 shares held after it.
- 4 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Canning John Charles bought about $14.0K of FEMY on Aug 7, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 3,125 shares held after it.
- 4 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Sipos Jeremy Alexander bought about $10.0K of FEMY on Aug 7, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 3,125 shares held after it.
- 4 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Clinical-Medical Affairs Mifek Jeffrey Gerald bought about $10.0K of FEMY on Aug 7, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$134.0K over 180 days
+$134.0K over 90 days
more than 74% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 95% of Medical Devices
Revenue
+40.8% year over year
more than 85% of Medical Devices
Margin
-812.3% net margin
below 96% of Medical Devices
Buybacks
no share repurchases reported
Short interest
8.4% of the float short (float per yahoo 2026-10-26) · 7.4 days to cover · settled 2026-09-30
more than 77% of Medical Devices
The situation: each line is one rule over one dataset
5 insiders independently bought a net $134.0K while the stock fell 82% over six months, with no planned sales queued.
Nantahala Capital Partners Limited Partnership disclosed a 5%+ stake (9.99%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FEMY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-88.4%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FEMY: institutional holders (13F)
13F holdings, latest reported quarter
1,867,987 sh
$7.8M
62,232 sh
$260.1K
52,511 sh
$219.5K
30,920 sh
$129.3K
18,777 sh
$78.5K
Congress trades in FEMY
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Nantahala Capital Partners Limited Partnership
Activist 13D · 2026-08-17
9.99%
Nantahala Capital Management, LLC
Activist 13D · 2026-08-17
9.99%
Wilmot B. Harkey
Activist 13D · 2026-08-17
9.99%
Daniel Mack
Activist 13D · 2026-08-17
9.99%
FEMY planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FEMY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$133.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$116.8K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$16.3K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$29.6K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$19.6K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$143.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $134.0K bought by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FEMY financials
Revenue growth
+40.8%
XBRL, annual
Net margin
-812.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FEMY
| FY Dec 2025 | $2.3M |
| FY Dec 2024 | $1.6M |
| FY Dec 2023 | $1.1M |
| FY Dec 2022 | $1.2M |
| FY Dec 2021 | $1.2M |
| Jun 2026 | $331.8K |
| Mar 2026 | $424.9K |
| Dec 2025 | $813.4K |
| Sep 2025 | $729.4K |
| Jun 2025 | $409.3K |
| Mar 2025 | $341.3K |
| Dec 2024 | $581.6K |
| Sep 2024 | $554.9K |
At each fiscal year end
Single quarter
Net margin, TTM
-511.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FEMY
| FY Dec 2025 | -812.3% |
| FY Dec 2024 | -1,155% |
| FY Dec 2023 | -1,329% |
| FY Dec 2022 | -944.6% |
| FY Dec 2021 | -639.0% |
| Jun 2026 | -1,347% |
| Mar 2026 | +199.1% |
| Dec 2025 | -485.7% |
| Sep 2025 | -575.1% |
| Jun 2025 | -1,121% |
| Mar 2025 | -1,728% |
| Dec 2024 | -881.0% |
| Sep 2024 | -974.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$18.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FEMY
| FY Dec 2025 | -$19.2M |
| FY Dec 2024 | -$20.2M |
| FY Dec 2023 | -$11.4M |
| FY Dec 2022 | -$11.1M |
| FY Dec 2021 | -$8.2M |
| Jun 2026 | -$3.9M |
| Mar 2026 | -$4.2M |
| Dec 2025 | -$4.3M |
| Sep 2025 | -$5.6M |
| Jun 2025 | -$4.4M |
| Mar 2025 | -$4.9M |
| Dec 2024 | -$5.2M |
| Sep 2024 | -$5.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-425.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FEMY
| FY Dec 2025 | -455.8% |
| FY Dec 2024 | -182.2% |
| FY Dec 2023 | -84.8% |
| FY Dec 2022 | -54.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | -425.0% |
| Mar 2026 | -256.0% |
| Dec 2025 | -455.8% |
| Sep 2025 | -376.2% |
| Jun 2025 | -329.5% |
| Mar 2025 | -239.9% |
| Dec 2024 | -182.2% |
| Sep 2024 | -220.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-90.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FEMY
| FY Dec 2025 | -112.3% |
| FY Dec 2024 | -93.6% |
| FY Dec 2023 | -63.8% |
| FY Dec 2022 | -50.1% |
| FY Dec 2021 | -41.7% |
| Jun 2026 | -90.3% |
| Mar 2026 | -79.8% |
| Dec 2025 | -112.3% |
| Sep 2025 | -124.2% |
| Jun 2025 | -123.4% |
| Mar 2025 | -112.2% |
| Dec 2024 | -93.6% |
| Sep 2024 | -119.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-313.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FEMY
| FY Dec 2025 | -167.9% |
| FY Dec 2024 | -124.5% |
| FY Dec 2023 | -72.4% |
| FY Dec 2022 | -54.9% |
| FY Dec 2021 | -52.8% |
| Jun 2026 | -313.1% |
| Mar 2026 | -194.9% |
| Dec 2025 | -167.9% |
| Sep 2025 | -191.6% |
| Jun 2025 | -185.7% |
| Mar 2025 | -155.5% |
| Dec 2024 | -124.5% |
| Sep 2024 | -138.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-153.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield FEMY
| FY Dec 2025 | -2.9% |
| FY Dec 2024 | -4.0% |
| FY Dec 2023 | -2.7% |
| FY Dec 2022 | -5.2% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -7.2% |
| Mar 2026 | -3.7% |
| Dec 2025 | -2.9% |
| Sep 2025 | -8.8% |
| Jun 2025 | -3.9% |
| Mar 2025 | -3.0% |
| Dec 2024 | -4.0% |
| Sep 2024 | -3.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FEMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | $1.1M | $1.2M |
| Gross profit | n/a | n/a | n/a | $764.3K |
| Operating income | -$17.6M | -$17.8M | -$14.5M | -$11.6M |
| Net income | -$18.6M | -$18.8M | -$14.2M | -$11.4M |
| EPS (diluted) | -0.47 | -0.85 | -0.93 | -0.96 |
| Operating cash flow | -$18.7M | -$19.4M | -$11.3M | -$10.7M |
| Cash | $9.3M | $3.5M | $21.7M | $13.0M |
| Buybacks | n/a | $60.8K | $230.0K | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
FEMY Stock Sonar score 5/7 axes
Find similar shapesCompareFEMY ranks highest on growth (85th percentile) and insider conviction (84th), and lowest on institutional and government (5th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FEMY filings, in plain words
Are Femasys insiders buying or selling FEMY?
In the 180 days to 2026-10-28, Femasys insiders were net buyers, a net $134.0K across purchases and sales reported on Form 4, by 5 buyers.
Read the full summary
In the 180 days to 2026-10-28, Femasys insiders were net buyers of FEMY, a net $134.0K across purchases and sales reported on Form 4 by 5 buyers. 5 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
